INCREASED SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTOR EXPRESSION AND RELEASE BY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION

被引:14
|
作者
KALINKOVICH, A
GELEZIUNAS, R
KEMPER, O
BELENKI, D
WALLACH, D
WAINBERG, MA
BENTWICH, Z
机构
[1] MCGILL UNIV,SIR MORTIMER B DAVIS JEWISH HOSP,LADY DAVIS INST,CTR AIDS,MONTREAL,PQ,CANADA
[2] WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL
来源
关键词
D O I
10.1089/jir.1995.15.749
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
High levels of circulating soluble tumor necrosis factor receptors (sTNF-R) are associated with HIV-1 infection and disease. To understand better this association, we have investigated p55 and p75 TNF-R expression on peripheral blood mononuclear cell (PBMC) subsets and in the promonocytic cell line U937, with or without HIV infection, Using flow cytometry and monoclonal antibodies both to sTNF-R and to PBMC subsets, TNF-R were found to be expressed mostly by monocytes and in decreasing amounts and intensity in the following order: CD14(+) cells > CD8(+) cells > CD4(+) cells, Expression of TNF-R was higher on cells obtained from HIV-infected than from noninfected subjects, and expression of p75 sTNF-R was much higher than that of p55 sTNF-R. Studying the U937 cells revealed that over 80% of the cells expressed both sTNF-R, but with greater fluorescence intensity in the HIV-1 chronically infected cells (U-937-IIIB), Treatment of the cells with PMA caused an accelerated release into the medium of both sTNF-R, with a sharp decline in their cell surface expression, Basal levels of mRNA transcripts for p75 TNF-R were higher in the U-937-IIIB cells than in the uninfected cells, but p55 TNF-R mRNA was expressed only in the HIV-l-infected cells, These findings show that HIV-1 infection is accompanied by predominant elevation of p75 TNF-R surface expression on monocytes and CD8(+) lymphocytes, and results in both increased message and expression of these receptors in monocytes, It is very likely that increased shedding of these receptors into the serum accounts for the increased serum levels of both sTNF-R found in HIV-infected people.
引用
收藏
页码:749 / 757
页数:9
相关论文
共 50 条
  • [31] TREATMENT TRIALS FOR PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
    NIU, MT
    STEIN, DS
    SCHNITTMAN, SM
    JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (06): : 1601 - 1602
  • [32] HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION IN A COMMUNITY OF SOUTHERN MOZAMBIQUE
    MENCARINI, P
    DELUCA, A
    GHIRGA, P
    VICHI, F
    ANTINORI, A
    MAIURO, G
    NOORMAHOMED, I
    TAMBURRINI, E
    TROPICAL AND GEOGRAPHICAL MEDICINE, 1991, 43 (1-2): : 39 - 41
  • [33] RADIOSENSITIVITY OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    CONWAY, B
    TOMFORD, WW
    CLINICAL INFECTIOUS DISEASES, 1992, 14 (04) : 978 - 979
  • [34] IGA NEPHROPATHY IN A CHILD WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
    TRACHTMAN, H
    GAUTHIER, B
    VINOGRAD, A
    VALDERRAMA, E
    PEDIATRIC NEPHROLOGY, 1991, 5 (06) : 724 - 726
  • [35] INFECTION OF ACCESSORY DENDRITIC CELLS BY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    LANGHOFF, E
    HASELTINE, WA
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1992, 99 (05) : S89 - S94
  • [36] VARIANTS OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    TOURNIER, JN
    VERRIER, B
    BIRON, FF
    MANDRAND, B
    PEYRAMOND, D
    MEDECINE ET MALADIES INFECTIEUSES, 1995, 25 (05): : 709 - 715
  • [37] HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 CANDIDATE VACCINE BREAKTHROUGH INFECTION
    MASCOLA, JR
    MCNEIL, JG
    JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (06): : 1636 - 1637
  • [38] HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION AND BREAST-MILK
    DEMARTINO, M
    TOVO, PA
    GALLI, L
    GABIANO, C
    ACTA PAEDIATRICA, 1994, 83 : 51 - 58
  • [39] COMBINATION THERAPY FOR INFECTION DUE TO HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    CALIENDO, AM
    HIRSCH, MS
    CLINICAL INFECTIOUS DISEASES, 1994, 18 (04) : 516 - 524
  • [40] MODULATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION OF HUMAN MONOCYTES BY IGA
    JANOFF, EN
    WAHL, SM
    THOMAS, K
    SMITH, PD
    JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (03): : 855 - 858